Literature DB >> 12684035

Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration.

Emma Pirilä1, Andrew Sharabi, Tuula Salo, Vito Quaranta, Hongmin Tu, Ritva Heljasvaara, Naohiko Koshikawa, Timo Sorsa, Päivi Maisi.   

Abstract

Matrix metalloproteinase (MMP)-2 and membrane type 1-MMP can process the laminin-5 (Ln-5) gamma2-chain, revealing a cryptic site inducing epithelial cell migration. We investigated whether other MMPs process the Ln-5 gamma2-chain and related their ability to induce epithelial cell migration. The N-terminal sequences of the MMP-3, -12, -13, and -20 processed 80kDa Ln-5 gamma2x-chains were identical whereas the N-terminus of the 80kDa(MMP-8) Ln-5 gamma2x-chain was not. MMP-3, -13, -14, and -20 induced MCF-7 cell migration over Ln-5 while MMP-8 was a poor inducer of MCF-7 cell migration. In conclusion, several MMPs can process the Ln-5 gamma2-chain and induce epithelial cell migration.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12684035     DOI： 10.1016/s0006-291x(03)00452-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  35 in total

Review 1.  Integrin clipping: a novel adhesion switch?

Authors:  Manolis C Demetriou; Anne E Cress
Journal:  J Cell Biochem       Date:  2004-01-01       Impact factor: 4.429

Review 2.  Regulation of matrix biology by matrix metalloproteinases.

Authors:  Joni D Mott; Zena Werb
Journal:  Curr Opin Cell Biol       Date:  2004-10       Impact factor: 8.382

3.  Comparison of rapid MMP-8 and interleukin-6 point-of-care tests to identify intra-amniotic inflammation/infection and impending preterm delivery in patients with preterm labor and intact membranes.

Authors:  Piya Chaemsaithong; Roberto Romero; Nikolina Docheva; Noppadol Chaiyasit; Gaurav Bhatti; Percy Pacora; Sonia S Hassan; Lami Yeo; Offer Erez
Journal:  J Matern Fetal Neonatal Med       Date:  2017-03-01

Review 4.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

Review 5.  Laminin-332-integrin interaction: a target for cancer therapy?

Authors:  Daisuke Tsuruta; Hiromi Kobayashi; Hisayoshi Imanishi; Koji Sugawara; Masamitsu Ishii; Jonathan C R Jones
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.

Authors:  Manisha Tripathi; Alka A Potdar; Hironobu Yamashita; Brandy Weidow; Peter T Cummings; Daniel Kirchhofer; Vito Quaranta
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

7.  Release of matrix metalloproteinase-8 during physiological trafficking and induced mobilization of human hematopoietic stem cells.

Authors:  Carolin Steinl; Mike Essl; Thomas D Schreiber; Konstanze Geiger; Lea Prokop; Stefan Stevanović; Oliver Pötz; Harald Abele; Johannes T Wessels; Wilhelm K Aicher; Gerd Klein
Journal:  Stem Cells Dev       Date:  2013-02-12       Impact factor: 3.272

Review 8.  Laminin-5 in epithelial tumour invasion.

Authors:  Masahiko Katayama; Kiyotoshi Sekiguchi
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

9.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Authors:  Manisha Tripathi; Srinivas Nandana; Hironobu Yamashita; Rajkumar Ganesan; Daniel Kirchhofer; Vito Quaranta
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

10.  Laminin gamma2 fragments are increased in the circulation of patients with early phase acute lung injury.

Authors:  Masahiko Katayama; Akitoshi Ishizaka; Michiie Sakamoto; Seitaro Fujishima; Kiyotoshi Sekiguchi; Koichiro Asano; Tomoko Betsuyaku; Toru Kotani; Lorraine B Ware; Michael A Matthay; Satoru Hashimoto
Journal:  Intensive Care Med       Date:  2009-11-26       Impact factor: 17.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.